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Background: We examined the clinical value of two serum markers of low-grade inflammation, C-reactive protein
(CRP) and receptor of advanced glycation products (RAGE), as prognostic indices for cognitive decline.
Methods: Patients with cognitive impairment (n = 377) and controls (n = 66) were examined by blood biochemistry
tests, including ELISAs of serum CRP and RAGE, the Mini-mental State Examination (MMSE) and Montreal Cognitive
Assessment (MoCA), and STEAM 1H-MRS of the left hippocampus and thalamus.
Results: Compared to the control group, the cognitive impairment group was older (63.10 ± 9.70 years vs. 55.09 ±
10.77 years, P = 0.000) and had fewer years of formal education (9.01 ± 4.01 vs. 12.94 ± 3.0, P = 0.000). There were no
significant differences in the frequencies of type 2 diabetes, hypertension, or hyperlipidemia between groups.
Serum CRP and RAGE were higher in the cognitive impairment group (CRP: 2.08 mg/L, range 1.07 − 3.36 mg/L vs.
0.21 mg/L, range 0.18 − 0.42 mg/L; RAGE: 4.01, range 2.49 − 5.71, vs. 2.28, range 1.84 − 3.03; P < 0.05 for both). In
patients with cognitive impairment, there were negative correlations between cognitive function (as measured by
MMSE and MoCA) and both CRP and RAGE levels (P < 0.05). Patients over 55 years exhibited a positive correlation
between CRP and myo-inositol peak area in the left hippocampus (P < 0.05), while there was no relationship
between RAGE and any metabolite (P > 0.05). Multiple linear regression revealed that CRP was influenced by
hypertension (P = 0.026) and cognitive impairment (P = 0.042).
Conclusions: Chronic low-grade inflammation is present in patients with cognitive impairment. Serum CRP, RAGE,
and left hippocampal myo-inositol may provide prognostic information on cognitive decline.Background
Inflammation contributes to the development and exacerba-
tion of cognitive decline in neurodegenerative diseases [1,2].
Individuals with C-reactive protein (CRP) concentrations >
3 mg/L are at significantly elevated risk for cardiovascular
disease [3] while high-normal levels (2 ~ 3 mg/L) indicate
low grade systemic inflammation [4]. Moreover, recent
studies have established a correlation between serum
CRP and cognitive impairment [5]. Another potential
biological marker of cognitive decline, receptor for ad-
vanced glycation end products (RAGE), was first* Correspondence: xxy195211@163.com
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reproduction in any medium, provided the oridentified as a signal transduction receptor for the
products of non-enzymatic glycation and oxidation of
proteins and lipids (AGEs) that accumulate in diabetes
and at inflammatory foci [6]. An association between
RAGE levels and cognitive impairment in Alzheimer’s
disease has been reported [7]. We evaluated the inter-
relationships among serum CRP, serum RAGE, neuro-
psychological assessment scores, and cerebral metabolites
associated with cognitive dysfunction to examine the role
of chronic low grade inflammation in cognitive decline
and metabolic changes in brain structures, such as the
hippocampus, critical for cognitive function.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Patients
Patients assessed for cognitive decline at an out-patient
department from September 2009 to November 2012
were recruited as the case group. Demographic parame-
ters, including age and educational status, general med-
ical condition as indicated by body mass index, personal
and family histories of hypertension, type 2 diabetes, and
stroke, and lifestyle risk factors such as smoking status,
were recorded. Inclusion criteria included (1) cognitive
decline for at least 6 months, (2) probable Alzheimer’s
disease according to NINCDS-ADRDA criteria, (3) right
handedness, and (4) Activity of Daily Living scale (ADL)
score ≤ 26, Global Deterioration Scale (GDS) score ≤ 3,
and Hamilton Depression scale (HAMD) score ≤ 7. Exclu-
sion criteria included (1) sudden onset of cognitive de-
cline, (2) history of neurological disease (e.g., large vessel
stroke, Parkinson’s disease, severe brain injury, seizure,
multiple sclerosis, brain infection, meningitis), (3) psychi-
atric illness (e.g., schizophrenia, bipolar disorder), (4) sub-
stance abuse (alcohol, drugs, or others), and (5) MRI
contraindications. All the participants provided written in-
formed consent before enrollment. In total, 377 patients
were recruited as the patient group and 66 subjects with-
out cognitive decline as the control group.
Assessments
Blood biochemistry
Fasting blood concentrations of glucose, glycosylated
hemoglobin, total triglycerides, total cholesterol, HDL-
cholesterol, LDL-cholesterol, apolipoprotein A, apolipo-
protein B, and apolipoprotein E were detected by standard
enzymatic assays. Radial artery blood pressure was mea-
sured by a standard blood pressure monitor (VP-2000,
Colin Medical Technology Corporation, Japan) after at
least 10 minutes of rest. Standard height and weight mea-
surements were used to calculated patient BMI.
C-Reactive Protein (CRP) and RAGE assays
Serum concentrations of CRP and RAGE were measured by
ELISA using 4 mL fasting blood drawn from the cubital vein
into coagulating tubes. Serum aliquots were stored at −80°C
until analysis. Prior to analysis, the serum sample was di-
luted 50-fold. Commercial ELISA kits for CRP (Human
High sensitivity) were obtained from USCN Life Science
and RAGE kits from BlueGene.
Neuropsychological evaluation
Cognitive assessments included the Mini-mental State
Examination (MMSE) and Montreal Cognitive Assessment
(MoCA). The MMSE consists of 10 items testing orienta-
tion, memory, attention, calculation, language (naming, re-
peating, auditory comprehension, reading, and writing)
and visual-spatial ability, for a maximum total score of 30.The MoCA tests 8 cognitive domains, visual-spatial ability,
attention, executive function, immediate memory, delayed
memory, language, abstraction, calculation, and orienta-
tion, for a maximum total score of 30. The normal MoCA
score is ≥26, with one point added if the subject has
fewer than 12 years of formal education. All tests were
administered and scored by a professional trained in
neuropsychometric testing.
Neuroimaging
1H-MRS parameters were as follows: echo time/repeti-
tion time TE = 9.4 ms, TR = 2000 ms, 128 excitations,
TA = 4 min 48 s, volume 1.0 cm3 from the left hippo-
campal gray matter and 1.5 cm3 from the left thalamic
gray matter. These regions were chosen because many
metabolites measured in these areas are related to cogni-
tive disorders. The chosen volumes were able to cover
the ROI as more as possible without mix of cerebral
spinal fluid or other region, and results of region smaller
than those above would cause deviation for slight move
from inevitable breath and heartbeat. The concen-
trations of N-Acetyl-L-aspartic acid (NAA), choline-
containing compounds, myo-inositol, and glutamate
were measured and reported as peak area. All images
were acquired by a professional radiology technician.
Data analyses
Data were analyzed using the Statistical Package for So-
cial Sciences (SPSS 18.0). A two-tailed alpha level of
0.05 was the criterion for significance.
Ethics
All the process was approved by the ethics committees
of Shanghai East Hospital Affiliated to Tongji University
and the study was operated in accordance with the
World Medical Association’s Declaration of Helsinki.
Results
A total of 443 participants were included in the final
sample, 377 patients in the cognitive impairment group
(178 men, 199 women) and 66 in the control group (38
men and 28 women). Demographic characteristics, indi-
ces of cardiovascular heath and metabolic disease, and
serum CRP and RAGE concentrations are presented in
Table 1.
Correlation among serum CRP, cognitive function, and
cerebral metabolism
Older age and lower education are generally accepted
risk factors for cognitive dysfunction, and both were an-
alyzed separately to avoid interference. Age was divided
into 4 ranges: 40–54 (Figure 1), 55–64 (Figure 2), 65–79
(Figure 3), and > 80 years (Figure 4). Subjects were di-
vided into two education groups according to whether
Table 1 Demographics, cardiovascular and metabolic
health status, and serum CRP and RAGE levels in




(n = 377) (n = 66)
Age (year) 63.10 ± 9.70 55.09 ± 10.77 −5.295 0.000
Gender (male) 178(47.2%) 38(57.6%) −1.256 0.209
Education (year) 9.01 ± 4.01 12.94 ± 3.0 −6.455 0.000
CRP (mg/L) 2.08(1.07,3.36) 0.21(0.18,0.42) −6.488 0.001
RAGE (ng/mL) 4.01(2.49,5.71) 2.28(1.84,3.03) −3.271 0.004
Hypertension 60.5% 54.5% −0.761 0.447
Diabetes 28.8% 38.7% −1.348 0.178
Triglycerides (mmol/L) 1.38(0.89, 1.87) 1.49(0.99,2.06) −0.831 0.406
LDL (mmol/L) 2.93(2.41,3.68) 3.22(2.67,4.18) −1.651 0.099
Smoking 34.1% 34.8% −0.151 0.880
BMI (Kg/m2) 23.58 ± 3.39 23.12 ± 2.63 −0.189 0.850
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off used to correct MoCA scores. Correlations among
CRP, cognitive function, and cerebral metabolites were
analyzed by Spearman correlation in the 8 subgroups de-
fined by the four age groups and two education groups.Figure 1 Correlations among serum CRP levels, cognitive assessmentSerum CRP was negatively correlated with MMSE and
MoCA assessment scores (p < 0.05). There was a positive
correlation between serum CRP and myo-inositol peak
area in the left hippocampus (p < 0.05). Other metabo-
lites measured by 1H-MRS were not significantly corre-
lated with neuropsychological evaluation scores or CRP
levels (Table 2).
Correlations among serum RAGE, cognitive function, and
cerebral metabolism
Serum RAGE was negatively correlated with MMSE and
MoCA scores (p < 0.05). However, there was no signifi-
cant negative correlation between serum RAGE and
NAA peak area as predicted, or with any other meta-
bolic changes in the left hippocampus (Table 3) or thal-
amus (p > 0.05) as measured by 1H-MRS.
Multiple liner regression analysis of factor related to CRP
The effects of serum CRP and RAGE on cardiovascular
parameters did not interact, so each was analyzed separ-
ately by multiple liner regression. There were no signifi-
cant associations for RAGE, while stepwise regression
showed that CRP was affected by hypertension (p = 0.026)
and cognitive impairment (p = 0.042). The coefficient of
determination of the regression analysis indicated that all, and myo-inositol in Age range: 40–54.
Figure 2 Correlations among serum CRP levels, cognitive assessment, and myo-inositol in Age range: 55–64.
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ity in serum CRP (p = 0.028).
Discussion
The clinical diagnosis of early stage cognitive impair-
ment depends primarily on neuropsychological assess-
ments because there are often no obvious structural
lesions or metabolic changes in the brain as revealed by
neuroimaging. Prognostic markers predictive of cogni-
tive decline in the earliest stages prior to measureable
impairments may facilitate timely intervention. Low
grade inflammation is a possible contributing factor to
cognitive decline and as such, indices of inflammation
may be indicative of early pathogenic processes in brain
regions associated with cognitive function. Pathological
changes in the brain are often not reflected by changes in
peripheral blood chemistry due to the blood brain barrier
(BBB), but neural inflammation may be manifested by
changes in peripheral blood if the BBB is disrupted by the
pathology. Thus, it is possible that inflammatory medi-
ators in peripheral blood may be the earliest signs of
neurodegenerative disease. With this information as
background, our target was to investigate the relation-
ship between peripheral systemic inflammation and
cerebral metabolism in AD cognitive decline.Indeed, we found that inflammation as reflected by
serum CRP was associated with cognition dysfunction.
The median serum CRP in our cognitive impairment
group was 2.08 mg/L, much higher than in the control
sample (0.21 mg/L). Furthermore, CRP was inversely
correlated with MMSE and MoCA scores in the total
patient population and in subgroups stratified by age
range and years of formal education (including the youn-
gest higher-education group). Serum CRP is regarded as
an independent risk factor for cardiovascular disease,
and previous studies also suggested a relationship to
cognitive decline [8-10], although no definitive mechan-
ism has been established. If CRP is elevated before meas-
urable cognitive decline, inflammation may contribute to
cognitive impairment or accelerate the deterioration. For
example, CRP can activate the complement system,
causing a series of immune cascade reactions leading to
neurodegeneration [11].
Serum CRP was also positively correlated with cerebral
myo-inositol as indicated by 1H-MRS in subjects over
55 and independent of years of formal education. Myo-
inositol is mainly found in astrocytes, and increases are in-
dicative of glia proliferation as occurs in reactive gliosis
[12]. Elevations of myo-inositol levels in Alzheimer’s dis-
ease patients have been interpreted as a sign of gliosis
Figure 3 Correlations among serum CRP levels, cognitive assessment, and myo-inositol in Age range: 65–79.
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are induced to proliferate when the BBB is compromised.
Potential mechanism of these results was supposed to
associate with the “leakage” of inflammation. Low grade
systemic inflammation mediated by CRP may lead to in-
creased BBB permeability, impairment of endothelial func-
tion, and toxic elevations of intracellular calcium [14]. The
intracellular second messenger inositol triphosphate(IP3)
is not efficiently derived from myo-inositol and so may be-
come depleted. This in turn would hinder calcium release
and cause the failure of conduction through gap junctions
between astrocytes, suppressing interstitial buffering func-
tions and leading to neuronal hyperexcitability [15]. On
the other hand, IP3 was found to associate with glioma by
mediating signal transduction for activation and prolifera-
tion of gliocyte [16,17]. A compromised BBB may lead to
release of inflammatory factors into the peripheral blood.
Thus, the peripheral blood may contain markers indicative
of neurodegenerative diseases like AD. But the precise
connection between CRP and mI would be further studied
and presented in future research.
Like CRP, RAGE is thought to impair cognition through
an immune inflammatory pathway. Yan [18] first found 2.5-
fold RAGE overexpession in AD brains. Evidence suggests
that RAGE expression is enhanced in the hippocampus andfrontal lobe, and that RAGE binds to β-amyloid (Aβ) [19].
β-Amyloid can permeate the BBB from circulating blood by
combining with RAGE in endothelial cells [20], triggering
amyloid aggregation and stimulating a complex chronic im-
mune inflammatory response. This immune activation is
neurotoxic and results in the pathological changes associ-
ated with AD [21]. The receptors RAGE, scavenger receptor,
and serine protease inhibitor complex receptor (SEC-R) me-
diate the adherence of Aβ to microglia, which stimulates
microglia activation. In turn, activated microglia release NO,
TNF-α, TGF-β, and other cytotoxic factors [22]. Studies
above all held the opinion that RAGE plays an important
role in AD progression via immune and inflammation, while
Different from the cellular RAGE measured by immunohis-
tochemical measurement in tissue, what our study chose
was a quantitative determination of its total level in serum,
which stood for the measurable RAGE in peripheral
blood. More efficacious RAGE existed in serum meant
more potential immune and inflammation by RAGE
antigen-antibody reaction would happen. Another popular
sample sRAGE( soluble receptor for advanced glycation
end products), the competitive receptor against RAGE, is
supposed to be a protective factor on AD cognition [23].
We would further study it and other else relevant recep-
tors or ligands in sequence.
Figure 4 Correlations among serum CRP levels, cognitive assessment, and myo-inositol in Age range: >80.
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tween RAGE and diabetes, plasma glucose, or glycosylated
hemoglobin. Cell activation due to AGE-RAGE interaction
can occur in normal tissue via chronic immune inflamma-
tion, and this is aggravated in diabetes complication [24].
To date, however, the mechanism of cell activation in sys-
temic diseases has not been defined. As expected, RAGE
was much higher in the cognitive impairment group. Dia-
betes patients assigned in our study were the peopleTable 2 Correlations among serum CRP levels, cognitive
function, and cerebral metabolism
Age
group
Education n To MMSE To MoCA To
myo-inositol
(years) (years) r p r p r p
40 − 54 ≤12 41 −0.756 0.025 −0.744 0.015 0.261 0.055
>12 31 −0.818 0.039 −0.716 0.019 0.163 0.063
55 − 64 ≤12 88 −0.672 0.021 −0.707 0.011 0.712 0.026
>12 47 −0.724 0.022 −0.738 0.023 0.747 0.029
65 − 79 ≤12 79 −0.655 0.017 −0.710 0.015 0.740 0.018
>12 35 −0.686 0.021 −0.719 0.027 0.754 0.021
>80 ≤12 39 −0.684 0.034 −0.633 0.028 0.670 0.036
>12 17 −0.810 0.036 −0.758 0.031 0.797 0.041
(Figures 1, 2, 3 and 4).without relevant complication, which might be involved in
this result.
RAGE was not associated with any metabolic change
in left hippocampus or thalamus. We predicted that
RAGE may correlate with NAA, a sensitive neuroimag-
ing biomarker indicative of neuronal integrity and func-
tion. In light of these results, we suggest that RAGE
impairs cognition via immune signaling pathways that
disrupt neuronal functions but do not damage neuronalTable 3 Correlations among serum RAGE, cognition
function, and cerebral metabolism
Age
group
Education n To MMSE To MoCA To NAA
(years) (years) r p r p r P
40 − 54 ≤12 41 −0.511 0.032 −0.625 0.024 −0.212 0.063
>12 31 −0.598 0.047 −0.456 0.037 −0.194 0.058
55 − 64 ≤12 88 −0.563 0.041 −0.604 0.028 −0.235 0.072
>12 47 −0.492 0.038 −0.462 0.033 −0.186 0.062
65 − 79 ≤12 79 −0.637 0.029 −0.693 0.019 −0.242 0.103
>12 35 −0.552 0.032 −0.721 0.025 −0.255 0.096
>80 ≤12 39 −0.648 0.030 −0.723 0.028 −0.267 0.078
>12 17 −0.562 0.026 −0.820 0.034 −0.321 0.089
Table 4 Multiple linear regression analysis of CRP
Independents B Std.
Error
Std. Coefficients(β) t p
b0 5.456 1.163 - 2.691 0.020
Gender 0.085 0.326 0.087 0.578 0.556
Age 0.045 0.201 0.399 0.305 0.762
Education −0.052 0.213 0.434 −0.319 0.751
Hypertension 0.469 0.224 0.324 2.096 0.026
Diabetes 1.343 0.788 0.565 1.251 0.064
Triglyceride −0.003 0.121 0.382 −0.016 0.987
LDL 0.158 0.354 0.255 1.075 0.289
Cognitive 2.245 0.969 0.294 2.316 0.042
Smoking 0.210 0.263 0.339 1.457 0.153
BMI index 0.096 0.342 0.278 0.647 0.521
R2 = 0.0603, F = 8.266, P = 0.028.
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microtrauma. In AD or cerebral ischemia concomitant
with myocardial infarction, metabolic changes such as
NAA reduction and myo-inositol elevation can be
detected in the hippocampus [25,26]. We hypothesized
that participants with cognitive impairment would have
higher serum CRP/RAGE and lower NAA, but found no
significant association between serum RAGE and any bio-
marker of cerebral metabolism. Whether RAGE can effect
cerebral metabolism is currently unknown, and we found
no evidence for such an effect. Nonetheless, RAGE
was associated with cognitive impairment, so a RAGE-
mediated immune inflammatory reaction may cause
cognitive impairment by highly localized effects on
neurocircuits.
Regression analysis revealed that hypertension and
cognitive impairment led to the elevation of CRP in
serum. Serum CRP is widely believed to be an independ-
ent predictor of heart attack and stroke as well as an in-
dependent risk factor for hypertension [27,28]. Results
from animal experiments indicate that low grade inflam-
mation can damage endothelial cells and reduce the gen-
eration of NO, which results in the overexpression of
angiotensin receptor-1 (AR-1). Overexpression of AR-1
activates the renin-angiotensin-aldosterone system and
causes hypertension [29]. However, the precise relation-
ship between CRP and hypertension remains unclear. In
our study cohort, most of the hypertensive patients were
clinically obese with characteristics of metabolic syn-
drome. Hypertension, obesity, hyperlipidemia, and dia-
betes, the main manifestations of metabolic syndrome,
do not always present simultaneously, while in obese pa-
tients, the presence of at least three of these manifesta-
tions can lead to CRP elevation [30]. Hypertension is a
significant predictor of cardiovascular events and is
strongly association with inflammation by CRP.We found no interrelationship between the level of
serum CRP and myo-inositol or other metabolites in the
left hippocampus of hypertensives stratified by disease
severity with or without cognitive impairment. Though
CRP was higher in hypertension patients, there was no
correlation between CRP (or RAGE) and brain metabo-
lites related to inflammation. However, there has been
little research on the influence of long-term chronic
hypertension on the blood brain barrier and glial re-
sponses, so it is possible that CRP does not cross the
BBB even if brain inflammation is present.
The cognitive impairment group was older than the
control group and had fewer years of formal education,
suggesting that a “cognitive reserve” in unafflicted indi-
viduals may prevent or mask cognitive impairment
[31,32]. There were no significant differences in the fre-
quencies of type 2 diabetes, hypertension, or hyperlipid-
emia between groups. Among these diseases, type 2
diabetes has been shown to negatively affect cognitive
function [33] but there was no difference in diabetes inci-
dence, plasma glucose, or glycosylated hemoglobin be-
tween groups. As metabolic syndrome progresses, diabetes
coexists with hypertension, hyperlipidemia, and even obes-
ity, leading to a low-grade inflammatory condition that ul-
timately impairs cognition [1]. The participants assigned to
the cognitive impairment group were mostly in the early
stages and demonstrated relatively mild impairments.
Moreover, one of our objectives was to assess risk factors
for cerebrovascular and cardiovascular diseases, and almost
all patients accepted appropriate treatments. This early
intervention may have contributed to the relatively mild ef-
fects on cognition.
Conclusions
We found significant correlations between cognitive im-
pairment and inflammatory markers in the peripheral
circulation. Thus, we have identified a possible non-
invasive method for detecting neuro-inflammation lead-
ing to cognitive dysfunction. One limitation of this study
is that we only detected two markers. Future studies will
assess additional markers, including interleukins, TNF,
interferon, and complement together in a larger patient
sample.
In sum, our data provide evidence that relatively high
levels of serum CRP and RAGE have a negative impact
on cognitive function. Additionally, there is a positive
correlation between serum CRP and myo-inositol in the
left hippocampus. Thus, serum CRP, RAGE, and myo-
inositol in the left hippocampus are candidate bio-
markers for cognitive diseases that warrant validation in
future studies.
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